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Abstract
Background: Clinical Pharmacist Practitioners are advanced practicing pharmacists in North Carolina that provide
disease-specific management. The purpose of this retrospective cohort study was to compare the efficacy and
charges from referrals to a Clinical Pharmacist Practitioner by the primary care provider, to those managed by a
primary care provider alone.
Methods: Patients were separated into cohorts depending if they had at least two appointments with a Clinical
Pharmacist Practitioner from November 2008 to November 2011. A primary care provider saw all patients at least
twice during the study period. Cohorts were then matched by age, gender, and disease states. Medicare billed data
was evaluated from outpatient visits related to hypertension, diabetes mellitus, and peripheral neuropathy, as well
as emergency department visits and inpatient admissions. Cost of medications was estimated using 2009 AWP data
corresponding to medication histories within the electronic medical record. Efficacy was defined as ability to reach
disease state goal determined using national guidelines and reduction in pain score. Efficacy was analyzed by
difference-in-differences test and all other numerical data tested by paired t-tests.
Results: The Clinical Pharmacist Practitioners cohort experienced more outpatient visits (1338 vs. 858, p < 0.001),
fewer emergency department visits (115 vs. 190, p < 0.05), and similar inpatient admissions (88 vs. 117, p > 0.05)
than the primary care providers cohort, respectively. The Clinical Pharmacist Practitioners cohort showed changes in
charges of +22.6 % for outpatient visits, −45.5 % emergency department visits, and −13.2 % inpatient admissions
relative to the primary care provider cohort. There was no difference in average daily medication cost (Clinical
Pharmacist Practitioners $38.52 vs. primary care providers $38.23, p = 0.97) or achievement of disease state goals.
Conclusion: APPLE-NC demonstrated that through referrals, Clinical Pharmacist Practitioners provide services
comparable in charges and efficacy to primary care providers. Consequently, the current increased need for primary
care practitioners can be met in part by increasing the utilization of advanced practice pharmacists for chronic
disease management.
Trial registration: This does not apply for this retrospective cohort study.
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Background
The implementation of the Affordable Care Act has in-
creased the eligibility of many Americans to receive
healthcare benefits resulting in a shortage of primary
care physicians [1]. Increasing use of non-physician pro-
viders, such as family nurse practitioners (FNPs) and
physician assistants (PAs), to provide primary care services
to patients may reduce the need for additional primary
care physicians [1]. Advanced practice pharmacists, who
by individual state regulations, can manage referred pa-
tients by initiating, changing, and discontinuing media-
tions for their patients, including controlled substances.
Collaborative Drug Therapy Management (CDTM),
whereby a physician and a pharmacist establish a collab-
orative practice agreement in which the pharmacist can
initiate, modify or continue drug therapy for a patient in
that practice, is permitted in 48 states and the District of
Columbia [2]. However, only four states allow pharma-
cists with prescriptive powers to manage the pharmaco-
therapy of referred patients: California, Montana, New
Mexico, and North Carolina [3, 4]. These states require
supplemental education and certification, including diag-
nosis and physical assessment training, for advanced
practice pharmacists [5].
In North Carolina, advanced practice pharmacists are
called Clinical Pharmacist Practitioners (CPPs). The
North Carolina Medical Practice Act, which states that
any pharmacist who is approved to perform medical
acts, tasks, and functions may use the title Clinical
Pharmacist Practitioner, was enacted by the North
Carolina General Assembly in 1999 [6, 7]. A pharmacist
is required to complete advanced training and to be ap-
proved by both the North Carolina Board of Pharmacy
and North Carolina Medical Board to qualify for CPP li-
censure [6, 8]. Currently, ambulatory patients can be re-
ferred to a CPP for chronic disease management, thus
decreasing their primary care provider (PCP) visits and
allowing the PCP to provide medical care to more
patients.
Interventions by clinically oriented pharmacists, who
have similar responsibilities to CPPs but do not have
additional diagnostic, physical assessment and pharma-
cotherapy management training, have been shown to im-
prove outcomes in patients with chronic diseases, such
as Diabetes mellitus (DM), hypertension (HTN), and
pain [9–11]. A study of 1016 hospitals in the United
States demonstrated a reduction in total costs of care
when clinical pharmacy services were present [12]. In a
recently published systematic review, clinical pharmacy
services were shown to be cost-effective or to provide a
good benefit-to-cost ratio [13].
The purpose of the APPLE-NC study was to establish
the clinical efficacy and charges from CPP referred inter-
ventions, as compared to interventions provided by
primary care providers (PCP: physicians, FNPs, and PAs)
through evaluation of outpatient visits (OPV), emergency
department visits (EDV), inpatient admissions (IA), and
medications prescribed in chronic disease management
of Medicare recipients. This study demonstrates the
utilization and value associated with CPP interventions
in a sample of Medicare patients by analyzing patient
chronic disease management and the charges associated
with that care.
Methods
Design
This was a retrospective, matched cohort study, from
November 2008 to November 2011. Participants were
Medicare beneficiaries enrolled at University of North
Carolina (UNC) Health Care, and seen at one of the
UNC multidisciplinary outpatient clinics. Patients were
seen by either the CPP as a referral from the patient’s
PCP (CPP-R), or the PCP alone (PCP-A). Physician
groups at UNC Healthcare System clinics holding formal
relationships with CPPs were utilized in this analysis.
Parameters collected to determine the impact of CPP-
provided patient care on overall expenditures included
clinical outcomes, laboratory results, number of OPV,
number of EDV and IA, medications and charges associ-
ated with each visit and admission. Medicare billed data
for OPV, EDV, and IA were provided by the UNC
Clinical Data Warehouse for Health (CDW-H) [14].
Inclusion and exclusion criteria
All Medicare patients who were internally referred to
the UNC outpatient clinics utilizing CPP services were
eligible for inclusion. All patients required an ICD-9
code for HTN, DM, or peripheral neuropathy (PN) in
their claims data. These disease states were selected be-
cause of their clinical interrelatedness, prevalence in the
United States, and the associated complexity of their
pharmacotherapy management. Patients were included
in the CPP-R cohort if they saw a CPP at least twice
during the 3-year study period, in addition to at least
two PCP visits. Patients were included in the PCP-A
cohort if they were not managed by a CPP and required
at least two visits to a PCP during the study period.
Dual Medicare/Medicaid recipients were excluded from
this study because costs paid by Medicaid could serve
to confound the costs associated with care and would
render the study less generalizable to other states and
health care systems.
Study outcomes
The primary study outcomes were the percentage of pa-
tients who reached their disease state goal, such as blood
pressure (BP) <140/90 mmHg for patients with HTN, or
glycosylated hemoglobin (HgbA1c) <7.0 % for patients
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with DM, or achieving a patient’s desired pain goal.
These goals were determined by the patient’s PCP based
on the patient’s age and comorbidities by using national
or international guidelines for management of HTN and
DM, such as the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC-7), the Inter-
national Society of Hypertension Guidelines, or the
American Diabetes Association Standards of Medical
Care in Diabetes.
The secondary outcomes were the number of and per-
cent change of charges of OPV, IA, and EDV for any
diagnosis, estimated cost of medications prescribed, and
the average number of therapy changes per year defined
as a dose increase or decrease, or drug initiation or
discontinuation. EDV and IA related to management
of HTN, DM, and pain were included in this study.
Clinical efficacy was determined by how well-controlled
patients’ disease states were with respect to biomarkers
and indicators, as compared with disease state goals set at
the baseline study visit. Baseline measurements of clinical
biomarkers (HgbA1c, BP) and indicators (Brief Pain In-
ventory score (BPI) were determined at the first visit
within the start of the 36-month period, provided that the
first visit was within six months from the beginning of the
study period. If the visits began later than May 1, 2009,
the baseline systolic BP was recorded from a routine visit
within 6 months of the beginning of the study period at a
clinic, or appointment that was not in the previously
specified clinics. These biomarkers were also recorded
at the last visit within the study period as an endpoint for
determining clinical efficacy.
The BP, HgbA1c, and BPI values were not recorded
for baseline characteristics or for the last visit if the pa-
tient was seen at the visit for an infectious illness, due to
its acute impact on these values. Urgent care, ED, and
inpatient biomarkers and indicators were also excluded
from baseline characteristics and from last visit data
collection as these visits may have reported elevated
BP, HgbA1c, and BPI scores due to an emergent, severe,
or febrile illness, which were not representative of chronic
disease management. If the BP was noted to be unusually
low or high, and the PCP recorded a second reading, both
BP readings were averaged for a final BP reading that was
included in the study. For patients that missed their
morning BP medications, the BP from the next available
appointment was used.
Each patient was assessed individually for the BP goal
set at the previous appointment to determine if the
current provider was able to meet that goal. When a
goal was not available in the medical record, the Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure (JNC-7) was consulted for BP values for patients
with HTN only, and the American Diabetes Association
Standards of Medical Care in Diabetes (ADA guidelines)
2008 through 2011 were consulted for appropriate
HgbA1c and BP goals [15–19]. ADA guidelines from the
appropriate year were followed for patients with concur-
rent DM and HTN.
Pain is subjective, and management goals are patient-
specific. A decrease in pain score or level is a general
goal of treatment, however, the specific decrease in score
or level differs between patients. Pain intensity scores
were assessed at the first and last visits, and determined
to be at goal if the pain score decreased by at least one
point on a scale of 1–10 [20]. A decrease in at least two
points in the pain intensity score was also analyzed.
Clinical efficacy was achieved if the biomarkers and in-
dicators improved or decreased at the last visit within
the study period, compared to the initial or baseline
measurement (e.g., a pain score of nine at the first visit
in the study, to a pain score of eight at the last visit in
the study). Measurements that remained unchanged at
the beginning and at the end of the study period were
not considered an improvement.
The number of disease-related EDV and IA were deter-
mined by screening the medical records of each patient.
HTN- and DM-related events and sequelae are listed in
the Additional file 1. Patients who did not have HTN,
DM, or PN were excluded from this analysis.
Patients were included in the charge analysis if they
received any program interventions through the UNC
outpatient clinics. Direct medical charges were defined
as the amount charged to Medicare by the patient’s health
plan for routine office visits, EDV, IA, procedures, and
other ancillary services. Charges associated with the pa-
tient’s covered visits were current for the date of the visits.
Therefore, charges were not annualized.
Medicare charges were also obtained for OPV, EDV,
and IA. As all costs were reported to Medicare at the
time of service, no adjustments were made for inflation.
The medical costs associated with the HTN-, DM-, and
chronic pain-related EDVs and IAs were determined
from CDW-H claims data.
Medication history
Prescribed medications were tracked using WebCIS, an
electronic medical record (EMR) utilized by UNC
Health Care during the study period. Only outpatient
prescription medications were included for cost analysis.
Herbal supplements, vitamins, minerals and medications
only available over-the-counter were excluded.
Medication and total cost calculation
All medications were priced according to 2009 average
wholesale price (AWP) listed within the 2010 edition of
Redbook [21]. The manufacturer with the lowest AWP
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was used for each medication. Manufacturers that re-
package medications list a wide range of AWPs. Thus,
repackagers were excluded to reduce variability when
comparing drug costs. All medications were assumed to
be generic unless only brand was available during 2009.
Medication cost was calculated by multiplying the num-
ber of drug units used during the treatment duration by
the AWP. Drug unit was defined as a tablet, milliliter of
solution, box of medication (e.g., inhaler, topical prod-
ucts). Medications prescribed on an as needed basis
were priced as a one-month supply if the prescription
directions recorded in the EMR indicated exact quan-
tities. If these PRN medications did not indicate quan-
tities, they were excluded from pricing and were only
evaluated for therapy changes. Treatment duration was
defined as time from first to last recorded medical visit.
Medication adherence was assumed to be 100 % for ana-
lysis of the data. Adherence rates are likely different for
patients receiving comprehensive services from phar-
macists compared to those only seen by primary care
providers, however these rates have not been well
established in the literature. Therefore, an adherence
rate of 100 % was used to ensure consistent analysis
of data in both cohorts without introducing additional
bias. The total cost was calculated by adding total es-
timated medication costs with OPV, EDV, and IA
charges for any chief complaint. This total cost was
divided by the number of days seen by a provider to
generate cost per day. Cost was standardized with
time to prevent the appearance of more expensive
treatment due to longer duration of care within the
study period. Similarly, total therapy changes were
standardized by year.
Analysis
Matched cohorts were created to reduce confounding
variables. ICD-9 codes for HTN, DM, and PN were used
to create a pool of patients eligible for randomization.
The 250.XX code was used to include patients with dia-
betic complications, which resulted in inclusion of Type
1 DM and Type 2 DM in this study.
Subjects were matched by age, gender, and disease
state using SAS software, version 9.2 (SAS Institute, Inc.,
Cary, NC (2008)). One hundred matches were randomly
generated and selected for inclusion into the study, using
a random number generator in Microsoft Excel 2013
(Microsoft, Redmond, WA). A power calculation for the
primary outcome using Power and Precision, version 2
(Biostat, Engelwood, NJ) found that a sample of 65 pa-
tients in each cohort would be needed to detect an effect
of 0.5, as defined by Cohen, with 80 % power using a
two-tailed t-test and an alpha of 0.05 [22]. The first 65
patient pairs were chosen to meet minimum power.
Efficacy endpoints were analyzed using a difference-in-
differences test and all other numerical data, such as dif-
ference in average medication cost per day per patient,
were analyzed using a paired t-test.
Results from the analysis of charges are reported as a
percent difference due to proprietary rights of charges
billed to patients by the UNC HealthCare System. This
study was approved by the Institutional Review Board of
the Office of Human Research Ethics at the University
of North Carolina at Chapel Hill.
Results
Demographics
During the study period, 12,957 patients were available
for inclusion into this study, and 503 patients were seen
by a CPP at least twice. When matched to the 12,065 pa-
tients in the PCP-A group, 378 patients were matched
according to gender, age, and disease state. Of these, 65
pairs were selected randomly and included for analysis
to meet minimum power while ensuring feasibility of
study completion. Although the data was matched using
ICD-9 codes, there were several discrepancies in the
medical records stating that a patient did or did not have
HTN, DM, or PN.
Patient characteristics were similar between both co-
horts (Additional file 1: Table S1). Baseline characteris-
tics of the CPP-R and PCP-A cohorts resulted in no
statistically significant differences regarding BMI (p =
0.85), average 10-year Atherosclerotic Cardiovascular
Disease (ASCVD) risk (p = 0.80), total serum cholesterol
(p = 0.86), and serum high density lipoprotein (p = 0.55)
(Table 1). Measurements of SBP and BPI recorded from
the first study visit were also non-significant between
the two cohorts (p = 0.27) (Table 1), however, signifi-
cantly higher baseline HgbA1c levels were recorded in
the CPP-R cohort compared to the PCP-A cohort (7.5
vs. 6.8, p = 0.02) (Table 1).
Visits and charges
Average OPV per patient in the CPP-R cohort were
significantly higher than the total number of OPV per
patient in the PCP-A cohort (20.6 vs 13.2, respect-
ively; p = 0.0002) (Table 1). The average charge associ-
ated with an outpatient CPP-R visit was 20.7 % lower
than the average charge associated with an outpatient
PCP-A visit (Table 2).
Patients who received health care services from a CPP
visited the ED less frequently, but this difference was not
statistically significant (1.7 vs 2.9, respectively; p = 0.06)
(Table 1). The total charge for EDV for any diagno-
sis, however, was 45.6 % lower in the CPP-R group
(Table 2).
Patients in the CPP-R cohort were admitted to an in-
patient service with an average of 1.4 IA vs. 1.8 IAs in
the PCP-A cohort, but the difference was not statistically
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significant (p = 0.32) (Table 1). Total IA charges associ-
ated with CPPs was 13.2 % lower than charges in the
PCP-A cohort, however charges associated with IA
related to HTN, DM, and/or pain in the CPP-R cohort re-
sulted in costs that were 30.4 % higher than in the PCP-A
cohort (Table 2).
Clinical efficacy
More patients were at or below their BP goal in the
CPP-R cohort at the beginning and at the end of the
study period than the PCP-A cohort, however the differ-
ence between the two cohorts did not achieve statistical
significance (p = 0.48) (Table 3). At the end of the study
period, patients treated by CPPs reached their HgbA1c
goal as often as patients in the PCP-A cohort (p = 0.21).
Pain scores decreased by one point on the pain scale in
26 patients (55.3 %) in the CPP-R cohort, compared to
13 patients (41.9 %) in the PCP-A cohort, which was not
statistically significant (p = 0.30). A decrease by two
points on the pain scale was also not significantly differ-
ent between cohorts (p = 0.47) (Table 3).
Table 2 Percent change of charges associated with outpatient
visits, emergency department visits, and inpatient admissions
between the CPP and PCP cohorts
% Change
Outpatient Visits
Outpatient Visit Charges 22.6
Charges per Visit −20.7
Emergency Department Visits
Total Emergency Department Visits Charges −45.6
Emergency Department charges related to HTN, DM, Pain 21.0
Inpatient Admissions
Total Inpatient Charges −13.2
Inpatient Charges related to HTN, DM, Pain 30.4
Due to proprietary concerns regarding Medicare charges, percent change was
used to show the difference in charges between the CPP and PCP cohorts. If
the value in the table above is negative, then the CPP cohort variable is n%
less than the PCP cohort variable. The converse is true for a positive number:
the CPP cohort variable is n% more than the PCP cohort. For example, the CPP
cohort resulted in 22.6 % higher outpatient visit charges and 20.7 % lower
outpatient charges per visit than the PCP cohort
Percent Change ¼ ðCPP value – PCP valueÞðCPP valueÞ  100
Table 1 Clinical characteristics of patients at baseline
CPP (n = 65) PCP (n = 65)
Mean 95 % CI Mean 95 % CI p-value
BMI 31.2 29.4–33.0 31.0 29.3–32.6 0.85
Average 10 year CVD risk 23.3 18.1–28.5 22.7 17.8–27.7 0.80
Systolic Blood Pressure Average 132.4 127.3–137.5 136.6 131.2–142.0 0.27
Total Cholesterol 184.2 169.4–199.0 182.4 168.0–196.8 0.86
High Density Lipoprotein 51.2 46.6–55.8 53.3 48.2–58.3 0.55
Hemoglobin A1c 7.5 6.8–8.2 6.8 6.2–7.3 0.02
Brief Pain Inventory Score 7.2 6.2–8.2 6.5 5.0–8.0 0.37
Outpatient Visitsa 20.6 18.2–22.9 13.2 10.5–15.9 0.0002
Primary Care Provider Visits 15.0 12.9–17.1 13.2 10.5–15.9 0.32
Clinical Pharmacist Practitioner Visitsb 5.6 4.6–6.7 0 N/A N/A
Emergency Department Visitsc 1.7 1.2–2.3 2.9 1.7–4.1 0.06
Emergency Department Visits related to HTN, DM, Paind 0.25 0.1–0.4 0.52 0.10–0.95 0.20
Inpatient Admissionse 1.4 0.8–1.9 1.8 1.0–2.6 0.32
Inpatient Admissions related to HTN, DM, Painf 0.5 0.1–0.9 0.4 0.2–0.5 0.51
aTotal outpatient visits: CPP cohort 1338 visits; PCP cohort 858 visits
bPatients in the PCP cohort did not receive treatment from CPPs, therefore, there were no CPP visits in the PCP, and a p-value was unable to be calculated
cEmergency Department visits: CPP 115 ED visits; PCP 190 ED visits
dEmergency Department visits related to HTN, DM, Pain: CPP 16 ED visits; PCP 34 ED visits
eInpatient Admissions: CPP 88 IA; PCP 117 IA
fInpatient Admissions related to HTN, DM, Pain: CPP 32 IA; PCP 23 IA
Table 3 Clinical efficacy of CPPs compared to PCPs
CPP PCP p-value*
Number (%) of patients with BP at goal
Beginning of study 36 (57.1) 30 (47.6) 0.48
End of Study 40 (63.5) 29 (46.0)
Number (%) of patients with HgbA1c at goal
Beginning of study 2 (7.1) 22 (61.1) 0.21
End of Study 7 (25.0) 23 (63.9)
Number (%) of patients with pain at goal
BPI score decreased by 1 point 26 (55.3) 13 (41.9) 0.30
BPI score decreased by 2 points 20 (40.4) 10 (32.2) 0.47
*p-value calculated using Difference in Differences test
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Medication cost per cohort
No statistical difference existed in the mean difference
of medication cost per day per patient between both co-
horts. The average medication cost per day per patient
was $38.52 in the CPP-R cohort, and $38.23 per day per
patient for the PCP-A patients (p = 0.97). Patients in the
CPP-R cohort experienced more changes to drug therap-
ies per year on average than patients in the PCP-A pa-
tients (21.1 vs. 15.1, respectively; p = 0.032) (Table 4).
Total cost
The total cost of OPV, EDV, IA, and prescribed medica-
tions in the CPP-R cohort was 1.46 % lower, as compared
to the PCP-A cohort (p = 0.026) (Data not shown due to
proprietary nature of data).
Discussion
Patient characteristics were similar between both co-
horts, however significantly higher baseline HgbA1c
levels were recorded in the CPP-R cohort as compared
to the PCP-A cohort. Lower charges were accrued by
the CPP-R cohort for their OPV, but visited the out-
patient clinics significantly more than patients in the
PCP-A cohort. There was no statistical difference be-
tween the EDV and IA between cohorts, and overall
charges accrued for EDV and IA were lower in the CPP-R
cohort. Patients reached their specific disease state goal in
both cohorts with no difference in the medication costs
per day for patients. The CPP-R cohort required more
drug therapy changes than the patients in the PCP-A co-
hort. The overall cost of OPV, EDV, IA, and prescribed
medications in the CPP-R cohort was significantly lower
than the overall cost in the PCP-A cohort.
Pharmacists are the most accessible healthcare profes-
sion and are considered to be underutilized to the extent
of their education [23]. Pharmacists are a cost-effective
addition to the health care team, as their pharmacothera-
peutic knowledge improves patient outcomes and de-
creases adverse events [5]. To date, most research has
focused on the benefits of clinical pharmacy services, such
as the Asheville Project in North Carolina [24]. More re-
cently, research on a pharmacist-PCP collaborative effort
in California demonstrated better health outcomes for
their patients than when utilizing only a PCP [25].
In practice, CPPs often manage high-risk patients with
multiple comorbidities, complex drug regimens, or patients
refractory to standard therapy [26, 27]. Patients referred to
clinical pharmacists by PCPs generally have multiple co-
morbidities, or are refractory to standard of care medica-
tions, as provided by their PCP [28–30]. As one example,
the HgbA1c percentage of the patients in the CPP-R co-
hort was significantly higher (p = 0.02) than patients in the
PCP-A cohort at the outset of the study. Patients in the
CPP-R cohort demonstrated more frequent OPV, EDV,
and IA than the patients in the PCP-A cohort, which may
be indicative of more complicated illnesses, or refractory-
to-standard treatment disease states in patients that were
referred to a CPP.
The difference in OPV charges is most likely due to
lack of recognition of pharmacists or CPPs as health
care providers under Medicare, and therefore, the inabil-
ity for CPPs to bill at Current Procedural Terminology
(CPT) codes higher than 99211 CPT code. The higher
cost associated with EDV and IA in the CPP-R cohort is
most likely related to more complex disease states re-
quiring more expensive treatment, or treatment for a
longer period of time.
In this study, clinical interventions by CPPs resulted in
patients reaching their BP, HgbA1c, and pain goals as
often as the PCP-A patients. Although BP and HgbA1c
goals were easy to measure, pain is subjective and diffi-
cult to treat due to its complexity of genetic, environ-
mental, social, and cognitive variables [31]. Due to the
complexity of pain management and lack of individual-
ized pain goals in the medical chart, clinical efficacy was
determined if the pain scores decreased by at least one
point at the end of the study period. A one to two point
reduction is considered the minimally accepted thresh-
old for determining clinical importance of chronic pain
management outcomes, based upon the IMMPACT re-
searchers’ findings in 2008 [20].
A recent retrospective pre-post study analysis revealed
clinical and cost-benefits of added CPPs in a neuro-
trauma intensive care unit setting [27]. The additional
CPPs provided therapeutic interventions and prevented
adverse drug events, resulting in an estimated 30 %
in cost-savings [27]. In this study, the overall charges
for health care were demonstrated to be higher in the
PCP-A cohort, although the charges associated with the
management of HTN, DM, and/or chronic pain in the
CPP-R cohort was higher. This suggests that patients in
the CPP-R group were more complex and had more
complicated medical conditions that necessitated higher
medical charges during EDVs and IAs.
The medication arm of the APPLE-NC study provided
an estimate of the total cost of medications prescribed
to PCP-A study patients, compared to those also man-
aged by CPPs. There was no significant difference in
medication cost between the two cohorts despite more
pharmacotherapy changes in the CPP-R cohort. The
Table 4 Average medication cost per day and therapy changes
per year
CPP PCP Mean difference P-value
Average medication
cost per day per patient
$ 38.52 $ 38.23 $ 0.29 0.97
Average therapy
change per year per patient
21.1 15.5 5.6 0.032
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non-significant difference between the cohorts may be
due to utilization of additional, lower cost medications
to optimize pharmacotherapy, more dose adjustments to
optimize therapy, or pharmacotherapy adjustments that
may not contribute to overall cost of medications.
With the inception of the Affordable Care Act, there is an
emphasis on finding affordable and effective health care. Im-
plementation of pharmacist-driven services represent one
possible solution to this problem, however, lack of reim-
bursement limits the utility of pharmacists as advanced prac-
ticing providers. Currently, there is momentum in Congress
for recognition of pharmacists as providers, with legislation
such as the Pharmacy and Medically Underserved Areas En-
hancement Act (H.R. 592), which would amend title XVIII
of the Social Security Act to cover pharmacist services. Add-
itional cost and outcomes data will aid the passing of federal
legislation that enable pharmacist reimbursement for the
clinical services they currently provide, however, limited data
exists to compare the cost-effectiveness of pharmacist inter-
ventions to those of PCPs. This study contributes to the ef-
forts for provider status by demonstrating advanced
practicing pharmacists can provide chronic hypertension,
diabetes mellitus, and chronic pain management in ambula-
tory care patients that matches those of PCPs.
Limitations
This study has several limitations to the interpretation
of the data. First, a small sample size was specifically uti-
lized in this retrospective cohort study. Also, medical
visits at facilities unaffiliated with UNC Health Care
were not used in this data analysis. Some data, such as
HTN or DM goals, were not reported in medical notes
because of omission or they were determined prior to
the study period. For the purposes of this study, goals
were determined by assessing each patient’s health sta-
tus, comorbidities, and the setting of a goal according to
the guidelines set forth by JNC-7 and ADA guidelines
when not available in medical notes.
Selection bias may have existed because patients re-
ferred to CPPs may have been more refractory to treat-
ment that was provided by the PCP alone, which is
considered as a standard of care. This bias may have
skewed study results due to variations in patient com-
plexity, such as seen with the higher HgbA1c levels.
Also, medication adherence issues cannot be excluded
with either cohort. It is assumed that patients prescribed
medications were adherent to prevent introducing bias
into the analysis, however, it is outside the scope of this
study to ascertain medication adherence in this retro-
spective analysis.
Although data were matched using ICD-9 codes, the
electronic health records documentation did not show a
HTN, DM, or PN diagnoses for several patients in the
cohort. This resulted in an unequal matching of disease
states between the cohorts, however the number of pa-
tients in each cohort remained the same and did not
affect the primary outcome. Documentation of the term
“peripheral neuropathy” or “PN” in the electronic health
record was poor or absent in patients with the ICD-9
codes for PN, and often PN was described as “pain” or
“chronic pain” in the electronic health record. Therefore,
BPI scores for chronic pain, documented in patients with
ICD-9 codes for HTN, DM, and PN, were included in
analysis. All patients were assessed for their level of pain
on a 0–10 scale at the beginning of their OPV, and all
patients were included in the study, provided that the
pain was chronic and managed by their CPP or PCP.
Pharmacies and healthcare systems may obtain medica-
tions at prices lower than AWP, depending upon con-
tractual agreements. The AWP was limited to one year,
2009, to reduce the effect of AWP variability that may
not translate directly to medication price fluctuations to
the consumer or third party plan.
Conclusion
In Medicare-eligible patients in North Carolina included
in the APPLE-NC study, CPPs were shown to be as ef-
fective as PCPs in chronic disease management. Study
patients tended to have higher HgbA1c levels, and were
more refractory to treatment, as demonstrated by the
higher emergency department and inpatient costs associ-
ated with HTN, DM, and chronic pain. This study dem-
onstrated that CPPs decreased overall EDV and IA, and
enabled their patients to reach BP and HgbA1c goals, as
well as to manage pain and to decrease pain scores.
Consequently, the current increased need for PCPs can
be met in part by increasing the utilization of advanced
practice pharmacists for chronic disease management
thereby allowing PCPs to provide care for new patients
or highly complex disease states. It is anticipated that
this study will motivate other health care systems across
the United States to replicate these results, provide justi-
fication for expanding the scope of pharmacy practice,
and continue to improve the quality and value in the
provision of patient care.
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